Deltex Medical Group PLC Investor Event
May 10 2018 - 1:01AM
RNS Non-Regulatory
TIDMDEMG
Deltex Medical Group PLC
10 May 2018
10 May 2018
Deltex Medical Group plc
("Deltex Medical", "Deltex" or "the Company")
Investor Event
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), announces that it will be
hosting an investor event on 22 May 2018 following the publication
of its full year results for the twelve months ended 31 December
2017.
The event will be held at Davy's at Woolgate Bar and Brasserie,
Woolgate Exchange, 25 Basinghall Street, London, EC2V 5HA from
18:00 and will take the form of a Company presentation followed by
a Q&A session. The presentation for the event will also be made
available on the Company's website.
Potential investors and shareholders who wish to attend the
event should register their interest with Florence Chandler at IFC
Advisory Ltd on florence.chandler@investor-focus.co.uk or on 020
3934 6636.
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@deltexmedical.com
Ewan Phillips, Chief Executive
Jonathan Shaw, Group Finance Director
Arden Partners plc (Nominated Adviser
& Broker) 020 7614 5900
Chris Hardie
Ciaran Walsh
Turner Pope Investments (TPI) Ltd
(Joint Broker) 0203 621 4120
Andy Thacker info@turnerpope.com
IFC Advisory Ltd (Financial Public
Relations) 0203 934 6630
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's proprietary ODM is the only
technology to measure blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhancedhaemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM which is proven
to reduce complications suffered by patients after surgery and save
hospitals the costs of treating those complications.
Deltex Medical's CardioQ-ODM+ platform also now provides
clinicians with two further advanced haemodynamic monitoring
technologies. High Definition Impedance Cardiography is an entirely
non-invasive monitoring technology which creates an electrical
field across the chest and measures the disruption to this field
when the heart pumps blood. Pulse Pressure Waveform Analysis uses
peripheral blood pressure signal analysis to give doctors
information on changes in the circulation and is particularly
suited to monitoring lower risk or haemodynamicallystable
patients.
Company goal
Haemodynamic management is now becoming widely accepted as an
important major new medical modality. Consequently, the Company's
focus is on maximising value from the opportunities presented as
enhanced haemodynamic management is adopted into routine clinical
practice around the world. The Company aims to provide clinicians
with a single platform, a 'haemodynamicworkstation', which offers
them a range of technologies from simple to sophisticated to be
deployed according to the patient's condition and skill and
expertise of the user. Doing this will enable the Company to
partner healthcare providers to support modern haemodynamic
management across the whole hospital.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAFKCDBABKDAPK
(END) Dow Jones Newswires
May 10, 2018 02:01 ET (06:01 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Apr 2024 to May 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2023 to May 2024